Bellerophon Therapeutics, Inc.
News
Why Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today?
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nBellerophon Therapeutics (BLPH) stock is losing value on Tuesday after the clinical-stage therapeutics company was sent a delisting...\n more…
The Latest Analyst Ratings for Bellerophon Therapeutics
Benzinga Bellerophon Therapeutics BLPH has observed the following analyst ratings within the last quarter: According to 4 analyst offering 12-month price targets in the last 3 months, Bellerophon Therapeutics has an average price target of $24.25 with a high of $35.00 and a low of $2.00.\n more…
Bellerophon Crashes after Disappointing Topline Data
TipRanks Financial Blog Shares of Bellerophon Therapeutics (NASDAQ: BLPH ) cratered in morning trading on Monday after the clinical-stage biotherapeutics company announced disappointing top-line data from its Phase 3 trial. This clinical trial was a randomized, double-blind, placebo-controlled Phase 3 study evaluating INOpulse in 145 patients.\n more…
Why Is Bellerophon Therapeutics (BLPH) Stock Down 79% Today?
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nBellerophon Therapeutics (BLPH) stock is taking a massive beating on Monday after the company posted poor clinical trial results.\nThe post Why Is Bellerophon Therapeutics (BLPH) Stock Down 79% Today? appeared first on InvestorPlace...\n more…
Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse(R) for Treatment of Fibrotic Interstitial Lung Disease
Globe Newswire Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse programs in PH-COPD and PH-SarcoidosisCompany to host conference call ...\n more…
Bellerophon Therapeutics (BLPH) Investor Presentations - Slideshow
SeekingAlpha The following slide deck was published by Bellerophon Therapeutics, Inc. in conjunction with this event. This article was written by Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage.\n more…